Symbol | Exchange | Currency |
|---|
IO Biotech (NASDAQ: IOBT) dosed first patient in its phase 3 clinical trial of lead drug candidate, IO102-IO103, in combination with Merck's KEYTRUDA® (pembrolizumab) in patients...
Part 1: A New Way to Kill Tumors–IO102-IO103 Phase 3 Trial in Combination with Anti-PD-1 in Advanced MelanomaThursday, April 28th @ 12:30pmETNEW YORK, April 22, 2022 (GLOBE...
NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on...
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Neutral | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Sell |
| Summary | Strong Buy | Strong Buy | Buy | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 20.70 | 20.70 | 20.70 | -0.23 | -1.10% | 1.10K | Toronto | |||
| 0.18 | 0.19 | 0.18 | 0.000 | 0.00% | 158.73K | TSXV | |||
| 66.36 | 67.84 | 66.36 | -1.57 | -2.31% | 200.00 | Toronto | |||
| 0.11 | 0.11 | 0.11 | 0.0000 | 0.00% | 63.71K | TSXV | |||
| 0.11 | 0.115 | 0.11 | 0.0000 | 0.00% | 228.97K | TSXV | |||
| 17.15 | 17.26 | 17.04 | +0.13 | +0.76% | 105.08K | Toronto | |||
| 0.51 | 0.58 | 0.50 | -0.06 | -10.53% | 55.99K | NEO | |||
| 3.47 | 3.57 | 3.41 | +0.040 | +1.17% | 1.42M | Toronto | |||
| 14.85 | 15.05 | 14.51 | +0.37 | +2.56% | 123.57K | Toronto | |||
| 1.55 | 1.55 | 1.47 | +0.07 | +4.73% | 417.55K | Toronto | |||
| 0.39 | 0.40 | 0.39 | +0.015 | +4.00% | 28.00K | CSE | |||
| 4.78 | 4.92 | 4.60 | +0.11 | +2.36% | 70.90K | Toronto | |||
| 0.325 | 0.34 | 0.32 | +0.0050 | +1.56% | 1.93M | Toronto | |||
| 0.97 | 1.12 | 0.95 | -0.090 | -8.49% | 1.67M | Toronto | |||
| 0.125 | 0.135 | 0.125 | 0.0000 | 0.00% | 466.23K | Toronto |